Mercaptopurine Accord-Uk

Mercaptopurine, the active ingredient in Mercaptopurine Accord-Uk, is a purine analog antimetabolite presented as an oral tablet for oral use. It is employed in the treatment of acute lymphoblastic leukemia, chronic myeloid leukemia, and inflammatory bowel disease such as Crohn's disease and ulcerative colitis.

GNH USA supplies Mercaptopurine Accord-Uk as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide, providing reliable, quality‑assured medication to meet the needs of clinical and research programs across the globe today.

Mercaptopurine is used in hematologic malignancies and inflammatory bowel disease to control abnormal cell proliferation and immune activity. - Acute lymphoblastic leukemia: helps achieve remission by targeting rapidly dividing lymphoblasts, decreasing blast count and improving survival outcomes. - Chronic myeloid leukemia: contributes to disease control by inhibiting leukemic cell proliferation, complementing tyrosine‑kinase inhibitor therapy in chronic‑phase patients. - Inflammatory bowel disease (Crohn's disease, ulcerative colitis): reduces intestinal inflammation and maintains remission, allowing reduction of corticosteroid dependence and improving quality of life.

Mercaptopurine may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Fatigue: decreased energy and stamina. - Myelosuppression: reduced blood cell counts such as neutropenia or anemia. - Elevated liver enzymes: mild transaminase increase.

Serious or Rare Side Effects: - Severe neutropenia: heightened infection risk. - Hepatotoxicity: significant liver injury requiring monitoring. - Pancreatitis: inflammation of the pancreas that may present with abdominal pain. - Secondary malignancies: rare therapy‑related cancers. - Bone marrow failure: profound suppression of hematopoiesis.

Before initiating therapy, clinicians should evaluate baseline labs and patient risk factors. - Monitor blood counts: perform regular CBC to detect myelosuppression. - Assess liver function: schedule periodic LFTs for hepatotoxicity. - Adjust dose in renal impairment: reduced clearance may increase toxicity. - Avoid use in pregnancy: category D, potential fetal harm. - Counsel on infection risk: advise prompt medical attention for fever or signs of infection. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture.

Mercaptopurine interacts with several drugs that can alter its metabolism or increase toxicity.

Major Interactions (Avoid): - Allopurinol: can markedly increase mercaptopurine toxicity; dose reduction is required. - Azathioprine: additive myelosuppression; concurrent use should be avoided. - TPMT inhibitors: elevate active metabolite levels, raising risk of severe toxicity.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect; monitor INR closely. - NSAIDs: can increase bone‑marrow suppression; watch blood counts. - Oral contraceptives: may reduce hormonal efficacy; consider alternative contraception.